Why bluebird bio, Celldex Therapeutics, and MannKind Are Today's 3 Best Stocks

The S&P 500 suffers its worst one-day loss in over a week while three clinical-stage biotech stocks run wild.

May 14, 2014 at 5:15PM

Despite a slower, but still steady stream of earnings reports, ongoing merger and acquisition rumors in the pharmaceutical sector, and mixed economic data, investors decided today would be the day to push the broad-based S&P 500 (SNPINDEX:^GSPC) lower and lock in some profits.

Longview

On the economic data front, the weekly Mortgage Bankers Associations' loan originations report showed a welcome 3.6% increase in refinancing and new mortgage loan activity, which builds on the 5.3% gain noted in the prior week. Overall loan originations are still well off their highs set a year ago, but it's encouraging with lending rates still near historic lows to see consumers taking advantage of these rates rather than sitting on the sidelines.

On the other hand, for a second straight month the Producer Price Index jumped notably, this time by 0.6%, which was well ahead of economists' forecasts. There's a tight line to walk when it comes to inflation in that we want to see prices moving higher as it demonstrates increasing demand. However, we also don't want to see prices surging, either, as it could cause consumers to spend less. Since consumer spending is such a vital component to U.S. GDP, a 0.5% gain in the PPI in March followed by a 0.6% gain in the PPI in April has to have investors wondering if a number of price hikes are on their way to consumers.

By days end the S&P 500 had retraced 8.92 points (0.47%), its worst one-day loss in more than a week, and closed at 1,888.53. Despite the move lower, three companies from the biotech sector helped lead optimists to higher ground.

Leading all companies to the upside today was clinical-stage biopharmaceutical company bluebird bio (NASDAQ:BLUE), which soared 27.3% after it reported its first-quarter results. For the quarter revenue soared to $6.3 million from $1.1 million in the year-ago quarter as its expenses more than doubled to $17 million and its loss swelled 63% to $10.5 million, or $0.44 per share. By comparison, Wall Street was expecting a narrower loss of just $0.32 per share.

But, it wasn't the details of its loss that got shareholders excited so much as the company's pipeline update which included the announcement that it expects to report initial clinical results in its beta-thalassemia major study (HGB-205) utilizing LentiGlobin at the European Hematology Association Congress next month. Investors are clearly pleased with the reporting timetable and are assuming based on the venue that the data has thus far been good – thus the share price shooting so much higher. As for me, I'd still suggest holstering that optimism until we see the upcoming data, but I'd have no qualms about you adding bluebird bio to your watchlist.

Images

Source: Alan Dean, Flickr.

Trailing not too far behind bluebird bio was Celldex Therapeutics (NASDAQ:CLDX) which shot higher by 26.9% after announcing a clinical trial collaboration with Bristol-Myers Squibb (NYSE:BMY). Under the terms of the agreement Bristol-Myers will pay Celldex $5 million upfront and the two will collaborate on multiple solid tumor phase 1/2 cancer studies utilizing Celldex's investigational CD-27-targeting antibody varlilumab, and Bristol-Myers' prized experimental anti-PD-1 inhibitor nivolumab. These studies are expected to start by the fourth-quarter of this year.

The deal itself is critical for Celldex in that if the combination therapy is successful it will have landed an experienced marketing partner. Yet, I'd also like to remind investors that Celldex's current valuation of $1.4 billion is extremely lofty considering that it's entirely clinical-stage. There are phase 3 studies worth watching, but until Celldex has an FDA approval under its belt it's probably not worth your investing money based on its current valuation.

Finally, shares of clinical-stage biopharmaceutical (noticing a trend today?) MannKind (NASDAQ:MNKD) took one giant leap higher, gaining 6.5%, after research firm Piper Jaffray upgraded the company to neutral from underweight and boosted its price target to $6.50 from $2.

Dreamboat
Next-generation Dreamboat inhaler. Source: MannKind.

The reasoning behind the upgrade was MannKind's confidence that inhaled diabetes therapy Afrezza will be approved by the Food and Drug Administration on or before its July 15 PDUFA decision date, and that the company may be getting close to finding a marketing partner. While the upgrade was probably overdue given Piper Jaffray's out-of-date price target, I still find plenty of reasons to be skeptical with MannKind's cash pile shrinking and the company still searching for a marketing partner after all these years. With execution risk a viable concern as well I believe investors have more than enough reason to stick to the sidelines in the meantime.

Although these three biotech stocks soared today, they'll likely have a tough time keeping pace with this top stock over the long run
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers